Systematic review with meta‐analysis: effect of inflammatory bowel disease therapy on lipid levels
Alimentary Pharmacology & Therapeutics2021Vol. 54(8), pp. 999–1012
Citations Over TimeTop 13% of 2021 papers
Jasmijn A M Sleutjes, Jeanine E. Roeters van Lennep, Eric Boersma, Luís Menchén, Matthias Laudes, Klaudia Farkas, Tamás Molnár, Nicholas A. Kennedy, Marieke Pierik, C. Janneke van der Woude, Annemarie C. de Vries
Abstract
Increase in total cholesterol levels was strongest for corticosteroids followed by tofacitinib but was not observed for anti-TNFα agents. Whether total cholesterol change associated with IBD treatment has an effect on cardiovascular risk requires further study.
Related Papers
- → Su1928 – Tofacitinib Improves Clinical Disease Activity in a Real-World Population of Patients with Moderate-Severe Ulcerative Colitis and Crohn’s Disease(2019)16 cited
- → The Use of Tofacitinib in the Treatment of Inflammatory Bowel Disease(2018)9 cited
- → Tofacitinib Adherence and Outcomes in Refractory Inflammatory Bowel Disease(2021)2 cited
- → Tu1730 – Improvement in Patient-Reported Inflammatory Bowel Disease Questionnaire Outcomes, and Relationship with Disease Activity, in Tofacitinib-Treated Patients with Ulcerative Colitis: Data from the Octave Clinical Trials(2019)1 cited
- → PCR80 Health-Related Quality of Life in Ulcerative Colitis Patients Treated With Tofacitinib in Randomized Controlled Trials: A Systematic Review and Meta-Analysis(2022)